Persistent Identifier
|
doi:10.7910/DVN/FPUH4R |
Publication Date
|
2023-12-14 |
Title
| Replication Data for: Where Do Those Data Go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya |
Author
| Downs, Louise O.University of Oxford, KEMRI-Wellcome Trust Research Programme
Campbell, CoriUniversity of Oxford
Abouyannis, MichaelKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Otiende, Mark.KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Kapulu, MelissaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Obiero, Christine W.KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Hamaluba, MaingaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Ngetsa, CarolineKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
Andersson, MoniqueUniversity of Oxford
Githinji, GeorgeKEMRI-Wellcome Trust Programme, Kilifi, Kenya
Warimwe, GeorgeKEMRI-Wellcome Trust Programme, Kilifi, Kenya
Baisley,KathyLondon School of Hygiene and Tropical Medicine
Scott, J. Anthony G.KEMRI-Wellcome Trust Programme, Kilifi, Kenya
Matthews, Philippa C.Francis Crick Institute, University College London, University College London Hospitals
Etyang, AnthonyKEMRI-Wellcome Trust Programme, Kilifi, Kenya |
Point of Contact
|
Use email button above to contact.
Downs, Louise O. (University of Oxford)
The Data Governance Committee (KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya) |
Description
| This is a replication dataset for the manuscript titled: "Where Do Those Data Go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya." .
This is a dataset summarising demographic, hepatitis B test results and alanine aminotransferase data from 6 completed different clinical trials conducted at KEMRI-Wellcome Trust Research Programme since 2016. The aim of this work was to give a seroprevalence estimate for HBV in Kilifi and also illustrate the amount of data that is likely available in this space that is currently underutilised. Data were accessed with permission from study PIs and from sponsors where necessary. These data were standardised for age and sex using the Kilifi health and demographic surveillance system (KHDSS) data as the standard population structure.
This data showed a crude HBsAg seroprevalence rate of 3.5%, which rose to 5% when standardised. There was considerable underrepresentation of women in these trials with 77% of participants being male. ALT was significantly higher in those who were HBsAg positive compared to negative, although was not outside the upper limit of normal for this population.
We argue from these results that routine collection and collation of both blood borne virus prevalence and liver function test information will enable better modelling of not only blood borne viruses, but also for estimating the burden from liver disease across the African region. This would be a low cost, efficient method that negates the need for the organisation of large sero-epidemiological surveys |
Subject
| Medicine, Health and Life Sciences |
Keyword
| Chronic hepatitis B
Clinical trials
Seroprevalence
Elimination Goals
Clinical care |
Notes
| Data Availability
Access to these data requires submission of a formal request for consideration by our Data Governance Committee. How to request
- Download and complete the data request form
- Email completed data request form to the Data Governance Committee at dgc@kemri-wellcome.org
|
Depositor
| Downs, Louise O. |
Deposit Date
| 2023-12-14 |